OPK · Opko Health, Inc.
$1.38
-0.02 (-1.43%)
At close · Aug 14
Market Cap
$1.03B
Shares
746.33M
Opko Health, Inc. Earnings Call Transcripts
Every quarterly earnings call for Opko Health, Inc. (OPK) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼53.4%
$179.74M
−$86.09M
'22 Q3
22-11-08
▼53.8%
$185.34M
−$85.23M
'22 Q4
23-02-23
▼27.8%
$237.58M
−$18.27M
'23 Q1
23-05-03
▼14.4%
$265.42M
−$19.64M
'23 Q2
23-08-03
▼0.6%
$178.59M
−$84.47M
'23 Q3
23-11-06
▼1.9%
$181.91M
−$66.48M
'23 Q4
24-02-27
▼26.9%
$173.69M
−$81.84M
'24 Q1
24-05-07
▼31.4%
$182.19M
−$10.30M
'24 Q2
24-08-07
▼2.8%
$173.63M
$24.89M
'24 Q3
24-11-07
▲1%
$183.64M
$14.03M
'24 Q4
25-02-27
▼13.7%
$149.95M
−$67.61M
'25 Q1
25-04-30
▼13.9%
$156.81M
−$148.44M
'25 Q2
25-07-31
▼12.6%
$151.67M
$21.63M
'25 Q3
25-10-29
▼19.2%
$148.45M
−$31.26M
'25 Q4
26-02-26
▼17.2%
$124.20M
−$54.85M
'26 Q1
26-04-28
LATEST
▲4.3%
$163.58M
−$8.42M
'26 Q2
26-07-27
Earnings call
FY26 · Q2
2026-07-27
Q2 2026 Financial Results Conference Call
Positive tone
GLP-1/Glucagon and Metabolic Programs
NGENLA Commercial Performance with Pfizer
2026 Financial Guidance
Revenue
$163.58M
▲ 4.3% YoY Diluted EPS
$-0.01
Gross margin
48.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-28
Opko Health, Inc. Q1 FY2026 Earnings Call
Positive tone
Strategic partnerships
Diagnostics and BioReference
MODX pipeline progress
Revenue
$124.20M
▼ 17.2% YoY Diluted EPS
$-0.07
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Opko Health, Inc. Q4 FY2025 Earnings Call
Confident tone
ModeX multi-specific antibody pipeline
Merck-partnered EBV vaccine
Diagnostics / BioReference turnaround
Revenue
$148.45M
▼ 19.2% YoY Diluted EPS
$-0.04
▼ 500% YoY Gross margin
43.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Opko Health, Inc. Q3 FY2025 Earnings Call
Positive tone
ModeX pipeline and clinical programs
BARDA-funded COVID antibody
Regeneron collaboration
Revenue
$151.67M
▼ 12.6% YoY Diluted EPS
$0.03
▲ 0% YoY Gross margin
32.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Opko Health, Inc. Q2 FY2025 Earnings Call
Positive tone
BioReference restructuring and Labcorp oncology sale
GLP-1/glucagon dual agonist (OPK-88006)
ModeX pipeline and EBV vaccine with Merck
Revenue
$156.81M
▼ 13.9% YoY Diluted EPS
$-0.19
Gross margin
31.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Opko Health, Inc. Q1 FY2025 Earnings Call
Positive tone
BioReference divestiture and restructuring
NGENLA / Pfizer partnership
Pharmaceutical pipeline progress
Revenue
$149.95M
▼ 13.7% YoY Diluted EPS
$-0.10
Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Opko Health, Inc. Q4 FY2024 Earnings Call
Confident tone
ModeX Pipeline and Multispecific Antibodies
BARDA Funding for Antiviral Programs
NGENLA Commercialization with Pfizer
Revenue
$183.64M
▲ 1% YoY Diluted EPS
$0.01
Gross margin
46.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Opko Health, Inc. Q3 FY2024 Earnings Call
Positive tone
BioReference restructuring and profitability path
ModeX immuno-oncology pipeline
BARDA funding for multispecific antibodies
Revenue
$173.63M
▼ 2.8% YoY Diluted EPS
$0.03
Gross margin
23.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Opko Health, Inc. Q2 FY2024 Earnings Call
Positive tone
BioReference Health Restructuring
NGENLA / Pfizer Partnership
ModeX Pipeline & Oncology Programs
Revenue
$182.19M
▼ 31.4% YoY Diluted EPS
$-0.01
Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Opko Health, Inc. Q1 FY2024 Earnings Call
Positive tone
NGENLA long-acting growth hormone launch
Pipeline development (oxyntomodulin, GLP-2, ModeX)
BioReference divestiture to LabCorp
Revenue
$173.69M
▼ 26.9% YoY Diluted EPS
$-0.12
Gross margin
24.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Opko Health, Inc. Q4 FY2023 Earnings Call
Positive tone
NGENLA launch and growth hormone franchise
ModeX collaborations and pipeline
Diagnostics / BioReference turnaround
Revenue
$181.91M
▼ 1.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Opko Health, Inc. Q3 FY2023 Earnings Call
Revenue
$178.59M
▼ 0.6% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Opko Health, Inc. Q2 FY2023 Earnings Call
Revenue
$265.42M
▼ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Opko Health, Inc. Q1 FY2023 Earnings Call
Revenue
$237.58M
▼ 27.8% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Opko Health, Inc. Q4 FY2022 Earnings Call
Revenue
$185.34M
▼ 53.8% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Opko Health, Inc. Q3 FY2022 Earnings Call
Revenue
$179.74M
▼ 53.4% YoY Diluted EPS
$-0.11
▼ 375% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Opko Health, Inc. Q2 FY2022 Earnings Call
Revenue
$309.89M
▼ 30% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Opko Health, Inc. Q1 FY2022 Earnings Call
Revenue
$329.22M
▼ 39.6% YoY Diluted EPS
$-0.08
▼ 260% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Opko Health, Inc. Q4 FY2021 Earnings Call
Revenue
$401.33M
▼ 18.9% YoY Diluted EPS
$-0.11
▼ 320% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Opko Health, Inc. Q3 FY2021 Earnings Call
Revenue
$385.81M
▼ 9.9% YoY Diluted EPS
$0.04
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Opko Health, Inc. Q2 FY2021 Earnings Call
Revenue
$442.41M
▲ 46.9% YoY Diluted EPS
$-0.03
▼ 160% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Opko Health, Inc. Q1 FY2021 Earnings Call
Revenue
$545.16M
▲ 157.8% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-18
Opko Health, Inc. Q4 FY2020 Earnings Call
Revenue
$494.68M
▲ 120.5% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Opko Health, Inc. Q3 FY2020 Earnings Call
Revenue
$428.06M
▲ 87.1% YoY Diluted EPS
$0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Opko Health, Inc. Q2 FY2020 Earnings Call
Revenue
$301.21M
▲ 33.1% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Opko Health, Inc. Q1 FY2020 Earnings Call
Revenue
$211.47M
▼ 4.9% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Opko Health, Inc. Q4 FY2019 Earnings Call
Revenue
$224.34M
▲ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
944809
CUSIP
68375N103
13F (30d)
205 filings
204 filers
Visit website
Investor relations